4-Sep-2026
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Globe Newswire (Mon, 24-Aug 4:00 AM ET)
Globe Newswire (Mon, 10-Aug 3:30 AM ET)
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Globe Newswire (Thu, 6-Aug 4:05 PM ET)
Globe Newswire (Mon, 3-Aug 4:00 AM ET)
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
Globe Newswire (Thu, 2-Jul 4:00 AM ET)
Globe Newswire (Tue, 23-Jun 5:46 PM ET)
Globe Newswire (Wed, 17-Jun 9:45 AM ET)
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Globe Newswire (Thu, 11-Jun 4:00 AM ET)
Globe Newswire (Tue, 9-Jun 4:00 AM ET)
Market Chameleon (Thu, 7-May 4:44 AM ET)
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Oculis Holding Ag - trades on the NASDAQ stock market under the symbol OCS.
As of September 4, 2026, OCS stock price was flat at $12.17 with 119,116 million shares trading.
OCS has a beta of 2.06, meaning it tends to be more sensitive to market movements. OCS has a correlation of 0.08 to the broad based SPY ETF.
OCS has a market cap of $703.51 million. This is considered a Small Cap stock.
Last quarter Oculis Holding Ag - reported $392,150 in Revenue and -$.20 earnings per share. This beat revenue expectation by $132,150 and exceeded earnings estimates by $.28.
In the last 3 years, OCS traded as high as $34.48 and as low as $9.05.
The top ETF exchange traded funds that OCS belongs to (by Net Assets): SBIO, BBC, ONEQ, GWX.
OCS has underperformed the market in the last year with a price return of -29.1% while the SPY ETF gained +19.8%. However, in the short term, OCS had mixed performance relative to the market. It has outperformed in the last 3 months, returning +2.9% vs +2.0% return in SPY. But in the last 2 weeks, OCS shares have been beat by the market, returning -7.0% compared to an SPY return of +0.6%.
OCS support price is $11.88 and resistance is $12.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCS shares will trade within this expected range on the day.